Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity.
B-Lymphocytes
/ drug effects
Biological Products
/ administration & dosage
Clinical Decision-Making
Desensitization, Immunologic
/ methods
Drug Hypersensitivity
/ diagnosis
Drug Therapy, Combination
/ methods
Humans
Immunoglobulin E
/ metabolism
Immunosuppressive Agents
/ administration & dosage
Lymphocyte Depletion
/ methods
Mast Cells
/ drug effects
Prevalence
Recombinant Proteins
/ administration & dosage
Risk Factors
Severity of Illness Index
Skin Tests
T-Lymphocytes
/ drug effects
Treatment Outcome
Adenovirus vector
Adverse drug reaction
Allergy
Complement
Cytokine storm
Gene transfer
Hypersensitivity
Hypogammaglobulinemia
Journal
Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
5
10
2021
Statut:
ppublish
Résumé
Biologic and other therapies used for the treatment of immune-mediated hypersensitivity conditions, and in people with immune-mediated hypersensitivity, can trigger a wide variety of immune-related adverse drug reactions and immunologically mediated drug hypersensitivities. These range from acute-onset immunoglobulin E-mediated allergies to delayed-onset T-cell-mediated hypersensitivities. Certain therapeutic and diagnostic agents can directly activate mast cells. Biologic agents used to treat immune-mediated hypersensitivity can also globally upregulate or downregulate the immune system leading to pathologic reactions, including cytokine storm and hypogammaglobulinemia.
Identifiants
pubmed: 33012325
pii: S0889-8561(20)30038-2
doi: 10.1016/j.iac.2020.06.003
pii:
doi:
Substances chimiques
Biological Products
0
Immunosuppressive Agents
0
Recombinant Proteins
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
635-647Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure E. Macy has received research grants to study drug allergy from ALK. He has served on data and safety monitoring boards for BioMarin and Audentes. He has performed consulting for Kalobios and Audentes. He is a member of the Ask an Expert Panel of the American Academy of Allergy, Asthma, and Immunology.